European guidelines for empirical antibacterial therapy for febrile
European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4 th European Conference on Infections in Leukemia by Diana Averbuch, Christina Orasch, Catherine Cordonnier, David M. Livermore, Małgorzata Mikulska, Claudio Viscoli, Inge C. Gyssens, Winfried V. Kern, Galina Klyasova, Oscar Marchetti, Dan Engelhard, and Murat Akova haematol Volume 98(12): 1826 -1835 December 9, 2013 © 2013 by Ferrata Storti Foundation
Infectious Diseases Society of America grading system for ranking recommendations. Diana Averbuch et al. Haematologica 2013; 98: 1826 -1835 © 2013 by Ferrata Storti Foundation
Major factors to consider when choosing empirical therapy for febrile neutropenic patients, based on the literature review (6, 8, 9, 18– 24, 26, 31, 35– 43, 51, 53, 54). Diana Averbuch et al. Haematologica 2013; 98: 1826 -1835 © 2013 by Ferrata Storti Foundation
ECIL-4 recommendation for initial empirical treatment in high-risk patients (anticipated to have neutropenia for more than 7 days), by indication and escalation or de-escalation approach. Diana Averbuch et al. Haematologica 2013; 98: 1826 -1835 © 2013 by Ferrata Storti Foundation
De-escalation approach: ECIL-4 guidelines for indications of initial specific regimens. Diana Averbuch et al. Haematologica 2013; 98: 1826 -1835 © 2013 by Ferrata Storti Foundation
Recommended strategies in various circumstances when using an escalation approach. Diana Averbuch et al. Haematologica 2013; 98: 1826 -1835 © 2013 by Ferrata Storti Foundation
Recommended strategies in various circumstances when using de-escalation approach. Diana Averbuch et al. Haematologica 2013; 98: 1826 -1835 © 2013 by Ferrata Storti Foundation
- Slides: 7